Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

HRMY - Harmony Biosciences Holdings, Inc.... | Finranks

Home

/

HRMY

H

Harmony Biosciences Holdings, Inc. (HRMY)

NGM – Real vaqt narxi. Valyuta: USD

39.30

-0.22 (-0.56%)

Bozor ochiq: Aug 12, 2026, 2:08 PM EDT

39.51

-0.01 (-0.03%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

4 Stocks Trading Near 52-Week High With More Upside Potential

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027 Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications Pitolisant GR NDA Accepted in July; Target PDUFA Date April 1, 2027 Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Date in 2028 Conference Call and Webcast Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa.